USA-based biotech Ultragenyx (Nasdaq: RARE) and Takeda Pharmaceutical (TYO: 4502), Japan's largest drugmaker, have joined forces in a strategic partnership to develop and commercialize therapies to treat rare genetic diseases.
Ultragenyx, which specializes in developing products in this field, will initially receive an exclusive license to one preclinical Takeda product candidate in a pre-determined area of use.
The San Francisco-based company will have a further exclusive option to co-develop and co-commercialize the product candidate in additional therapeutic areas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze